Last updated: July 7, 2026
Exelixis v. Intas (1:26-cv-00814): Litigation Summary, Patent Claims, and Potential Generic Entry Impact
Executive summary
- Case: Exelixis, Inc. v. Intas Pharmaceuticals Ltd.
- Court/docket: U.S. District Court, 1:26-cv-00814
- Core issue: Patent infringement and related relief tied to an Exelixis product and/or its Orange Book-listed patents, asserted against Intas in the context of generic or alternative entry under Hatch-Waxman.
- Business impact to watch: Whether the asserted patents include composition, formulation, method-of-use, or manufacturing claims, and whether Intas’s application is likely positioned for a Paragraph IV attack or a carve-out/section 505(b)(2) pathway. The scope and claim selection drive both design-around feasibility and the timing risk for generic launch.
No litigation filings, claim charts, complaint text, or patent list were provided in the prompt. Without the underlying docket contents (complaint, answers, motions, and PTAB/Fed. Cir. activity if any), a complete and accurate litigation summary cannot be produced.
What patents are at issue in Exelixis v. Intas 1:26-cv-00814?
Answer (required for an infringement and exclusivity-risk analysis): Not available from the provided information.
Which type of claims are typically asserted in Exelixis Orange Book cases
When Exelixis sues generics, the asserted families commonly include:
- Composition-of-matter (API identity/chemical structure)
- Formulation (tablet/capsule composition, coating, excipients)
- Method-of-use (patient population, dosing regimen, treatment line)
- Manufacturing (process parameters, intermediates, polymorph/solid-state)
- Adjunct/kit claims (combination use if applicable)
A litigation-grade summary requires the actual asserted patents, claims, and the alleged infringement theory from the complaint and claim chart.
What is the litigation status timeline for 1:26-cv-00814 (key dates, motions, hearings)?
Answer: Not available from the provided information.
A proper status timeline needs, at minimum:
- complaint filing date
- service date
- answer or Rule 12 posture
- scheduling order milestones (Markman schedule, fact discovery, expert reports)
- any early motions (dismissal, transfer, stay)
- PTAB actions (inter partes review, post-grant review) if filed
Has Intas filed a Paragraph IV certification in Exelixis v. Intas, and what exclusivity does it target?
Answer: Not available from the provided information.
A Hatch-Waxman posture analysis requires:
- which FDA application is at issue (ANDA/BLA/505(b)(2))
- certification type (Paragraph IV vs others)
- the Orange Book listed patents asserted
- whether the case implicates statutory exclusivity (for example, NCE, pediatric, orphan, 3-year/5-year protections) in addition to listed patents
How strong is Exelixis’s patent estate in this case versus Intas’s likely design-around paths?
Answer: Not available from the provided information.
Strength modeling depends on:
- claim scope (Markush breadth, functional language, dependent claim narrowing)
- prior art landscape
- prosecution history and estoppel risks
- whether the asserted claims are likely to be found not infringed if the generic changes crystalline form, salt, particle size, dissolution profile, or excipient system
- whether manufacturing/process claims are at issue
What settlement terms or consent judgments are on record in 1:26-cv-00814?
Answer: Not available from the provided information.
Settlement analysis requires:
- docket entries for consent judgments
- any published agreement terms
- stipulations on carve-outs, launch dates, or partial dismissals
Which companies are challenging Exelixis patents alongside Intas for the same product?
Answer: Not available from the provided information.
Parallel challengers can be identified only by linking:
- the same FDA reference product
- the same Orange Book patent set
- concurrent ANDA litigation/notice letters and related case captions
What is the Orange Book status of the patents asserted by Exelixis against Intas?
Answer: Not available from the provided information.
This requires:
- the Orange Book listings for the asserted NDA/BLA
- patent expiration dates (including PTA and pediatric extensions)
- listed method-of-use and formulation patents and their expiration windows
Could this litigation stay FDA approval or trigger an automatic 30-month stay?
Answer: Not available from the provided information.
A stay depends on:
- whether the case is triggered by an ANDA filing with a Paragraph IV certification
- the timing of the lawsuit relative to FDA acceptance and notice
- any dismissals or amended certifications
How does Exelixis v. Intas compare with other Exelixis generic patent litigations (judge, venue, pattern of claims)?
Answer: Not available from the provided information.
Comparison requires:
- the identity of the drug/product in suit
- asserted patent families and claim categories
- prior cases involving the same judge and similar claim sets
Key Takeaways
- Docket identified: Exelixis, Inc. v. Intas Pharmaceuticals Ltd., 1:26-cv-00814.
- Litigation-grade summary not possible from the provided data because the record lacks the complaint, asserted patent numbers, claim allegations, and docket events.
- Any credible analysis of patent strength, infringement scope, exclusivity exposure, and generic launch risk requires the underlying filings and Orange Book linkage that are not included here.
FAQs
- What patents does Exelixis assert against Intas in 1:26-cv-00814?
- Which claims (composition, formulation, method-of-use, manufacturing) are alleged to be infringed?
- Is the case based on a Paragraph IV certification, and what Orange Book patents are targeted?
- What are the next scheduled litigation steps in the docket for 1:26-cv-00814?
- Does the lawsuit impose a 30-month stay on FDA approval for Intas’s application?
References
- U.S. District Court docket for Exelixis, Inc. v. Intas Pharmaceuticals Ltd., 1:26-cv-00814.
